BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AVANIR Pharmaceuticals (AVN) Acquires Additional Rights To IriSys, Inc.'s Neurodex Technology; $1,925,000 In Cash; 2,000,000 Shares Of AVANIR Class A common stock


10/19/2005 5:12:57 PM

SAN DIEGO--(BUSINESS WIRE)--March 9, 2005--AVANIR Pharmaceuticals (AMEX:AVN - News) today announced that, through a wholly owned subsidiary, it has acquired from IriSys, Inc. additional rights to Neurodex(TM), AVANIR's late-stage drug candidate for the treatment of multiple central nervous system disorders, which was sublicensed from IriSys in 2000. As a result, AVANIR, through its subsidiary, holds the exclusive worldwide marketing rights to Neurodex for five indications under a royalty-bearing license with the owner of the underlying technology, The Center for Neurologic Study. Going forward, AVANIR will be obligated to pay The Center for Neurologic Study milestones, a patent royalty on product sales, and a share of revenues received if AVANIR sublicenses Neurodex to a third party. AVANIR will have no future financial obligation to IriSys. IriSys was paid $1,925,000 in cash and received 2,000,000 shares of AVANIR Class A common stock in the transaction. The value of the transaction will be recorded in the Company's financial statements as the sum of the cash paid and the fair market value of the common stock transferred to IriSys. The shares of common stock will be registered for resale, but will be subject to certain resale limitations under applicable law. The transaction eliminates the following payments that would have been due to IriSys: milestone payments, royalties in the mid-single digits payable on sales of Neurodex by AVANIR, and a share of any future royalties that AVANIR may have received from potential licensees. Other than future payment obligations to The Center for Neurologic Study, AVANIR and its subsidiary did not assume any liabilities of IriSys.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES